Dehydroepiandrosterone inhibits the growth of DMBA-induced rat mammary carcinoma via the androgen receptor

Oncology Reports

Volumn 5, Issue 1, 1998, Pages 241-243

  Boccuzzi, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Androgen receptor; Dehydroepiandrosterone; DMBA; Mammary tumor; Rat

Indexed keywords

ANDROGEN RECEPTOR; PRASTERONE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CHEMICAL CARCINOGENESIS; DRUG RECEPTOR BINDING; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DEHYDROEPIANDROSTERONE; FEMALE; FLUTAMIDE; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; TIME FACTORS;

EID: 0031985175     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Morales AJ, Nolan JJ, Nelson JC and Yen SS: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78: 1360-1367, 1994.
2. Nestler JE, Barlascini CO, Clore JN and Blackard WG: Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal man. J Clin Endocrinol Metab 66: 57-61, 1988.
3. Coleman DL, Leiter EH and Schwizer RW: Therapeutic effects of dehydroepiandosterone (DHEA) in diabetic mice. Diabetes 31: 830-833, 1982.